Live Feeds
● LIVE Updated 52m ago · 26 sources tracked

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

Moderna and Merck are pursuing FDA approval for intismeran autogene, a personalized mRNA cancer vaccine. In a late-stage trial of 1,137 melanoma patients, the vaccine paired with Keytruda produced statistically significant improvements in distant-metastasis-free survival and recurrence-free survival. The treatment uses a computer algorithm to create genetic instructions that train the immune system to target specific cancers. Following the trial results, Moderna shares rose 176% and Merck shares increased 12.6% on August 19.

RSS Source map (26)

What changed

No new information regarding the Moderna and Merck melanoma trial has been reported since the August 19 stock movement.

Live updates

  1. Moderna and Merck seek FDA approval for personalized mRNA melanoma vaccine

    Moderna and Merck are pursuing FDA approval for intismeran autogene, a personalized mRNA cancer vaccine. In a late-stage trial of 1,137 melanoma patients, the vaccine paired with Keytruda produced statistically significant improvements in distant-metastasis-free survival and recurrence-free survival. The treatment uses a computer algorithm to create genetic instructions that train the immune system to target specific cancers. Following the trial results, Moderna shares rose 176% and Merck shares increased 12.6% on August 19.

    Why it matters

    This treatment represents a shift toward personalized oncology by tailoring vaccines to individual patient tumors. The trial's success focuses on reducing the likelihood of cancer returning or spreading. The market reaction indicates high investor expectations for mRNA applications beyond infectious diseases.

    What is confirmed

    • Moderna and Merck are seeking FDA approval for a personalized mRNA cancer vaccine called intismeran autogene.
    • A late-stage trial involving 1,137 melanoma patients showed statistically significant improvements in recurrence-free survival and distant-metastasis-free survival when the vaccine was paired with Keytruda.
    • The vaccine utilizes a computer algorithm to generate genetic instructions that train the immune system to target individual cancers.
    • Moderna stock rose 176% and Merck stock increased 12.6% on August 19 following the trial results.

    What to watch next

    • FDA decision on the approval of intismeran autogene
    • Publication of peer-reviewed data from the 1,137-patient trial
    Sources used for this update (12)
    1. jen.jiji.com — He is 53, she is 24: a surprise marriage proposal arrives on La volta buona
    2. jen.jiji.com — Ica Day, organized models and integrated processes to prevent infections
    3. finance.biggo.com — Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs
    4. jen.jiji.com — US Open, today Zverev-Khachanov: schedule, head-to-head and where to watch it on TV
    5. jen.jiji.com — Venice Exhibition, Brizé receives the Special Award of the Film Impresa Award
    6. jen.jiji.com — Good start for Vanoli, Fiorentina wins 4-2 in Venice with a Mastantuono hat-trick
    7. jen.jiji.com — Ultimate Championship, it's Jacobs' turn: the Azzurri competing today in the 'World of Worlds' and where to watch them
    8. jen.jiji.com — Denise Cosco's death: apartment seized, second mobile phone also being analyzed
    9. jen.jiji.com — MotoGp, Bezzecchi crashes in San Marino and Marquez flies to the top of the World Championship: order of arrival and riders' standings
    10. www.pymnts.com — Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
    11. jen.jiji.com — Cancers: nasopharyngeal, in Italy 63% of the disease burden affects those under 65 (2)
    12. jen.jiji.com — Germany, Bild: "Drone crashes near armed forces base"
    confidence 100%

  2. Moderna and Merck Seek FDA Approval for Personalized mRNA Melanoma Vaccine

    Moderna and Merck are pursuing FDA approval for intismeran autogene, a personalized mRNA cancer vaccine. In a late-stage trial involving 1,137 melanoma patients, the treatment paired with Keytruda produced statistically significant improvements in recurrence-free survival and distant-metastasis-free survival. The vaccine utilizes a computer algorithm to generate genetic instructions that train the immune system to target individual cancers. Following the trial results, Moderna stock rose 176% and Merck stock increased 12.6% on August 19.

    Why it matters

    This treatment represents a shift toward custom-made vaccines tailored to the genetic profile of a patient's specific tumor. By combining mRNA technology with existing immunotherapy, the developers aim to reduce the likelihood of cancer returning or spreading. The success of the trial marks a potential new era in oncology.

    What is confirmed

    • Intismeran autogene showed statistically significant improvements in recurrence-free and distant-metastasis-free survival for 1,137 melanoma patients when used with Keytruda.
    • Moderna and Merck are seeking FDA approval for the treatment.
    • Moderna stock closed 176% higher and Merck stock closed 12.6% higher on August 19.
    • The vaccine uses a computer algorithm to determine genetic instructions.

    What to watch next

    • FDA decision on the approval of intismeran autogene
    • Publication of peer-reviewed data from the late-stage melanoma trial
    Sources used for this update (14)
    1. jen.jiji.com — US Open, today Musetti-Fery: schedule, head-to-head and where to watch it on TV
    2. jen.jiji.com — Salvatore Giglia, the 26-year-old who suffered burns while trying to put out a fire in Ciminna, has died
    3. jen.jiji.com — USA, Bank of America Vice President is the woman stabbed to death in Times Square
    4. jen.jiji.com — Media on Leipzig, 2 suspects identified, have ties to Russia
    5. jen.jiji.com — Venice Film Festival, Clooney receives Golden Lion for Lifetime Achievement: "Art doesn't stop wars but is an antidote against fear"
    6. jen.jiji.com — Vuelta a España, today 14th stage: schedule, route and where to watch it
    7. www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
    8. jen.jiji.com — AfD triumphs with 44% in Saxony-Anhalt, who is Ulrich Siegmund: "The most dangerous man in Germany"
    9. jen.jiji.com — Juventus, Locatelli's anxiety: injury against Milan, risk of surgery
    10. jen.jiji.com — United Kingdom, flight chaos: from Heathrow to Gatwick, take-offs are stopped. What's happening
    11. jen.jiji.com — Champions League, today's results: successes for Aston Villa and Aek, Porto-City on the field
    12. jen.jiji.com — Tumors: early breast cancer, over 30,000 genomic tests prescribed in Italy in 5 years (2)
    confidence 100%

  3. Experts hail Moderna and Merck mRNA cancer vaccine as start of custom-made era

    Cancer experts describe the successful late-stage trial of intismeran autogene as the beginning of an era for custom-made vaccines that train immune systems to fight individual cancers. The personalized mRNA treatment, developed by Moderna and Merck, showed statistically significant improvements in distant-metastasis-free and recurrence-free survival for 1,137 melanoma patients when paired with Keytruda. Following the announcement, Moderna stock closed 176% higher and Merck stock closed 12.6% higher on August 19. The companies are now seeking FDA approval for the treatment, which uses a computer algorithm to determine genetic instructions.

    Why it matters

    This development represents a shift toward personalized medicine using mRNA platforms beyond infectious diseases. Intismeran autogene would be the first drug approved with genetic instructions determined by a computer algorithm. Previous efforts to create similar cancer vaccines faced a century of failures.

    What is confirmed

    • Moderna and Merck are seeking FDA approval for intismeran autogene.
    • A Phase 3 trial of 1,137 melanoma patients using the vaccine with Keytruda showed statistically significant improvements in recurrence-free and distant-metastasis-free survival.
    • Moderna stock closed 176% higher on August 19.
    • Merck stock closed 12.6% higher on August 19.

    Still unconfirmed

    • Cancer experts hail the breakthrough as the beginning of an era of custom-made vaccines.

    What to watch next

    • FDA decision on the approval of intismeran autogene
    • Expansion of the mRNA platform to indications other than melanoma
    Sources used for this update (9)
    1. jen.jiji.com — Extreme heat doesn't let up in the South, fiery weekend ahead: today 6 red alerts, respite in the North
    2. jen.jiji.com — Grosseto, man found dead in an artificial pond: he had disappeared from home
    3. jen.jiji.com — Di Battista hospitalized in Cuba, reactions. From Crosetto to Mannoia: "Go Ale"
    4. jen.jiji.com — Falls from third-floor balcony, 16-year-old dies in Savona
    5. jen.jiji.com — US Open, today Djokovic-Navone: schedule, head-to-head, and where to watch it on TV
    6. tucson.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
    7. jen.jiji.com — North Korea, 'hostile US policy, response will be tough'
    8. jen.jiji.com — Frank Matano has become a dad: "So grateful to have you in my life"
    9. finance.yahoo.com — Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging
    confidence 90%

  4. Moderna and Merck cancer vaccine uses computer algorithm for mRNA instructions

    Moderna and Merck are seeking FDA approval for intismeran autogene, a personalized mRNA cancer vaccine that would be the first medicine approved with genetic instructions determined by a computer algorithm. The treatment showed statistically significant improvements in recurrence-free and distant-metastasis-free survival during a Phase 3 trial of 1,137 melanoma patients when used with the drug Keytruda. While Merck shares reached a record $152.20 on August 19, Moderna stock has since fluctuated as investors evaluate the potential of the broader mRNA platform against this single indication.

    Why it matters

    The INTerpath-001 study marks a shift toward personalized oncology where AI-driven design replaces traditional generic formulations. Success in melanoma could validate the use of similar mRNA platforms for other cancer types. The market reaction reflects a tension between the immediate clinical win and long-term valuation models.

    What is confirmed

    • The intismeran autogene Phase 3 trial involved 1,137 patients.
    • Combining the vaccine with Keytruda improved distant-metastasis-free survival and recurrence-free survival.
    • Merck shares reached $152.20 on August 19.

    Still unconfirmed

    • The vaccine would be the first approved medicine whose mRNA genetic instructions are determined by a computer.
    • Moderna stock experienced a pullback on August 24 due to profit-taking and valuation resets.

    What to watch next

    • FDA decision on the approval of intismeran autogene
    • Clinical trial results for other cancer indications using the same mRNA platform
    Sources used for this update (10)
    1. jen.jiji.com — Bari, Frenchman arrested at port: transporting 3 war missiles in a van
    2. jen.jiji.com — Vuelta a España, today fifth stage: schedule, route and where to watch it
    3. www.statnews.com — Sword Health to acquire Headspace, according to filing
    4. www.ad-hoc-news.de — Moderna's Post-Breakthrough Hangover: When the Rally Outruns the Models
    5. san.com — A cancer vaccine breakthrough, medical AI faces a reality check and recalls pile up
    6. jen.jiji.com — US-Russia, Trump: "I spoke with Putin, he will not attack any NATO country"
    7. jen.jiji.com — Trump: "Putin will not attack NATO territories" - Video
    8. www.statnews.com — The mystery of Moderna’s magic algorithm
    9. jen.jiji.com — Plane collides with truck in New York: "Two controllers left work early"
    10. jen.jiji.com — Cancers: Sailing and sun, the challenge to melanoma prevention among young people begins (2)
    confidence 90%

  5. Moderna and Merck Phase 3 Trial Validates Personalized Melanoma Vaccine

    Moderna and Merck have successfully completed a Phase 3 trial for intismeran autogene, a personalized mRNA cancer vaccine. The INTerpath-001 study involving 1,137 patients showed that combining the vaccine with the immunotherapy drug Keytruda produced statistically significant improvements in distant-metastasis-free survival and recurrence-free survival. This result allows the companies to seek FDA approval for the treatment. While Merck shares hit a record $152.20 on August 19, Moderna stock experienced a pullback on August 24 due to profit-taking and valuation resets following an initial surge.

    Why it matters

    The therapy targets tumors specific to each patient by pairing a neoantigen vaccine with pembrolizumab. This development follows a decade of work overcoming logistical challenges and pandemic-era obstacles. It represents a shift toward using vaccines to train the immune system to identify and kill cancer cells.

    What is confirmed

    • The Phase 3 INTerpath-001 study included 1,137 patients.
    • Intismeran autogene combined with Keytruda showed statistically significant improvements in recurrence-free and distant-metastasis-free survival.
    • Merck shares rose 12.6% to a record $152.20 on August 19.
    • Moderna and Merck spent a decade overcoming logistical and pandemic-era obstacles to develop the vaccine.

    Still unconfirmed

    • Moderna shares rose over 170 percent in one session.
    • Analysts maintained cautious ratings and price targets below temporary peak levels for Moderna.

    What to watch next

    • FDA approval application and decision timeline
    • Clinical trial data for other cancer types beyond melanoma
    Sources used for this update (7)
    1. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
    2. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    3. www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Down by 5.13% on Aug 24: A Full Analysis
    4. www.statnews.com — Medicaid transgender care rule sets precedent that could restrict coverage of other drugs
    5. finance.yahoo.com — Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?
    6. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
    7. www.koreatimes.co.kr — A cancer vaccine is closer than ever
    confidence 90%

  6. Moderna and Merck mRNA vaccine prevents melanoma recurrence in phase 3 trial

    Moderna and Merck announced Wednesday that an experimental personalized mRNA vaccine kept melanoma from returning or spreading in high-risk patients. The phase 3 clinical trial involved more than 1,000 participants. This treatment pairs a neoantigen vaccine with the immunotherapy drug pembrolizumab to target tumors specific to each patient. The trial marks the final clinical stage required before the companies can apply for FDA approval. Following the news, Moderna shares rose over 170 percent in one session.

    Why it matters

    Personalized vaccines represent a shift toward therapies tailored to an individual's specific tumor mutations. This approach aims to improve long-term outcomes for patients at high risk of skin cancer recurrence.

    What is confirmed

    • A personalized mRNA vaccine combined with pembrolizumab reduced melanoma recurrence and spread.
    • The phase 3 trial included more than 1,000 patients.
    • Moderna and Merck developed the experimental treatment.

    What to watch next

    • FDA approval application and decision
    • Long-term survival data from the phase 3 cohort
    Sources used for this update (4)
    1. omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
    2. news.lee.net — Week in review: Test your knowledge of notable news
    3. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
    4. www.statnews.com — FDA pauses Regenxbio gene therapy trial again due to safety concerns
    confidence 100%

  7. Moderna and Merck mRNA vaccine reduces melanoma recurrence in phase 3 trial

    Moderna and Merck developed a personalized mRNA cancer vaccine that significantly reduced melanoma recurrence during a phase 3 clinical trial. The treatment combines a neoantigen vaccine with the immunotherapy drug pembrolizumab. This success marks the final clinical step before the companies can seek FDA approval. Following the announcement, Moderna shares surged more than 170 percent in a single session. The trial results suggest the treatment could lead to a new generation of therapies tailored to the specific tumors of individual patients.

    Why it matters

    Melanoma is a dangerous form of skin cancer prone to returning after initial treatment. Personalized vaccines aim to train the immune system to recognize unique markers on a patient's specific tumor. This approach differs from traditional one-size-fits-all cancer medications.

    What is confirmed

    • The personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma recurrence in a phase 3 trial.
    • The vaccine has completed phase 3 clinical trials, which is the final step before FDA approval.
    • Moderna and Merck co-developed the neoantigen treatment.
    • Moderna shares surged more than 170 percent in one session following the trial results.

    What to watch next

    • FDA approval decision for the personalized mRNA vaccine
    • Publication of full peer-reviewed data from the phase 3 trial
    Sources used for this update (6)
    1. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    2. www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
    3. www.medicalnewstoday.com — Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
    4. www.statnews.com — HHS document offers new clues to Kennedy’s vaccine plans
    5. biz.heraldcorp.com — 'The COVID hero is back': Moderna shares surge 177% on cancer vaccine trial success
    6. www.wpr.org — Wisconsin doctor responds to ‘breakthrough trial’ of new cancer vaccine
    confidence 100%

  8. Moderna and Merck mRNA melanoma vaccine succeeds in late-stage trial

    Moderna and Merck reported that their mRNA cancer vaccine succeeded in a late-stage clinical trial for melanoma. The announcement triggered a massive surge in Moderna stock, with reports on the increase varying from 60% to a doubling of the share price. This development suggests the vaccine shows promise in treating advanced skin cancer, marking a potential shift in cancer treatment methodologies. The companies are positioning the results as a success in the late-stage testing phase.

    Why it matters

    The vaccine utilizes mRNA technology, the same platform used for COVID-19 vaccines, to target cancer cells. Melanoma is a severe form of skin cancer that often requires aggressive intervention. Success in late-stage trials is the final major hurdle before regulatory approval and widespread clinical use.

    What is confirmed

    • Moderna and Merck developed an mRNA cancer vaccine that succeeded in a late-stage melanoma trial.
    • Moderna stock prices rose significantly following the trial results.

    Still unconfirmed

    • Moderna shares soared 90%.
    • Moderna shares soared 60%.
    • Moderna's stock doubled.

    What to watch next

    • Regulatory filing and approval decisions from health authorities
    • Detailed publication of trial data including efficacy and safety metrics
    • Expansion of trials to other cancer types
    Sources used for this update (5)
    1. STAT — Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
    2. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    3. MarketWatch — Moderna’s stock doubles on promising cancer-vaccine results
    4. The Washington Post — Cancer treatment could face landmark moment with promising vaccine
    5. Financial Times — Moderna shares soar 60% on melanoma vaccine trial success
    confidence 90%